Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946505 | 0.85 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9KDM4EALDH1A1 | |
| SCHEMBL7974570 | 0.85 | CYP1A2 (0.50) | CYP2C19CYP1A2CYP2C9KDM4EMAPK1 | |
| SCHEMBL13950244 | 0.85 | CYP1A2 (0.50) | CYP2C19CYP1A2CYP2C9KDM4ETSHR | |
| SCHEMBL6481609 | 0.85 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9KDM4EALDH1A1 | |
| SCHEMBL6481604 | 0.85 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9KDM4EALDH1A1 | |
| SCHEMBL28576999 | 0.85 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9KDM4EMAPK1 | |
| SCHEMBL28577000 | 0.85 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9KDM4EMAPK1 | |
| SCHEMBL10813669 | 0.85 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9KDM4EMAPK1 | |
| SCHEMBL10553210 | 0.85 | ALDH1A1 (0.52) | CYP2C19CYP1A2CYP2C9KDM4ETSHR | |
| SCHEMBL10550998 | 0.85 | ALDH1A1 (0.52) | CYP2C19CYP1A2CYP2C9KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433204-B | Synthesis method and application of spiro-expandable monomer with multi-benzene ring structure | 深圳市安伯斯科技有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-115433204-A | Synthetic method and application of spiro-expansible monomer with multi-benzene ring structure | 深圳市安伯斯科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| US-4540650-A | Photoresists suitable for forming relief structures of highly heat-resistant polymers | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-09-10 | — | — | US | claimed |
| CN-115433204-B | Synthesis method and application of spiro-expandable monomer with multi-benzene ring structure | 深圳市安伯斯科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-115433204-B | Synthesis method and application of spiro-expandable monomer with multi-benzene ring structure | 深圳市安伯斯科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-112174960-B | Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-113024547-B | Bicyclic heterocycles as FGFR4 inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-115433204-A | Synthetic method and application of spiro-expansible monomer with multi-benzene ring structure | 深圳市安伯斯科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115433204-A | Synthetic method and application of spiro-expansible monomer with multi-benzene ring structure | 深圳市安伯斯科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-109641885-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-0403132-A2 | Monocarbamate diols, polymers derived from them, and NLO-active materials therefrom | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4831109-A | Copolymerizable UV stabilizers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-05-16 | — | — | US | disclosed |
| US-4691059-A | Copolymerizable UV stabilizers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0213925-A2 | Copolymerizable UV stabilizers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-03-11 | — | — | EP | disclosed |
| EP-0103225-B1 | PHOTORESIST FOR CREATING RELIEF STRUCTURES ON HIGH-TEMPERATURE RESISTANT POLYMERS | MERCK PATENT GmbH (DE) | 1987-02-04 | — | — | EP | disclosed |
| US-4540650-A | Photoresists suitable for forming relief structures of highly heat-resistant polymers | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-09-10 | — | — | US | disclosed |
| EP-0103225-A2 | Photoresist for creating relief structures on high-temperature resistant polymers | MERCK PATENT GmbH (DE) | 1984-03-21 | — | — | EP | disclosed |
| EP-0099525-A2 | Photoresist | MERCK PATENT GmbH (DE) | 1984-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | CYP2C19 505/4885CYP1A2 961/4885CYP2C9 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.